National Cancer Institute National Cancer Institute
U.S. National Institutes of Health National Cancer Institute
NCI Home Cancer Topics Clinical Trials Cancer Statistics Research & Funding News About NCI

Clinical Trial Results

Summaries of Newsworthy Clinical Trial Results

< Back to Main

Page Options
Print This Page  Print This Page
E-Mail This Document  E-Mail This Document
Browse by Cancer Type
Breast Cancer

Lung Cancer

Prostate Cancer

More Results
Search Trial Results

    Search  
Quick Links
Director's Corner

Dictionary of Cancer Terms

NCI Drug Dictionary

Funding Opportunities

NCI Publications

Advisory Boards and Groups

Science Serving People

Español
NCI Highlights
Restructuring the NCI Clinical Trials Enterprise

Clinical Trials Reporting Program

Coordinating Center for Clinical Trials

States Requiring Coverage of Clinical Trial Costs
Related Pages
Breast Cancer Home Page
NCI's gateway for information about breast cancer.

Search for Clinical Trials
NCI's PDQ® Cancer Clinical Trials Registry.
Breast Cancer Trial Results
16.  Ovary-Suppressing Drugs Can Prevent Return of Breast Cancer
(Posted: 06/25/2007) - In premenopausal women with hormone-sensitive breast cancer, drugs that stop the ovaries from functioning - thus shutting off the body's main source of the hormone estrogen - reduced the rates of relapse and of death following relapse when given in addition to tamoxifen, chemotherapy, or both, according to the May 19, 2007, Lancet.

17.  Heart Problems From Trastuzumab (Herceptin®) Do Not Increase in the Short Term
(Posted: 06/25/2007) - Women with breast cancer who take the drug trastuzumab (Herceptin®) are at risk of heart problems during treatment. Now a study has shown that the incidence of such problems does not increase in the short term, though the long-term effects remain unknown, according to findings presented at the 2007 ASCO meeting in Chicago.

18.  Studies Affirm Tamoxifen's Long-Term Preventive Benefit
(Posted: 03/07/2007) - Long-term follow-up data from two cancer prevention trials have confirmed that women at high risk for breast cancer continue to receive a risk-reduction benefit from tamoxifen years after they have stopped taking it, according to the Feb. 21, 2007, Journal of the National Cancer Institute.

19.  Study Confirms Risk of Bone Loss for Patients Taking Exemestane
(Posted: 02/14/2007) - Women who switched to the drug exemestane after taking tamoxifen to prevent a breast cancer relapse lost more bone density and had a higher risk of bone fractures than women who continued taking tamoxifen, according to a report published online Jan. 26, 2007, by Lancet Oncology.

20.  Zoledronic Acid Prevents Bone Loss During Estrogen-Suppression Treatment of Breast Cancer
(Posted: 01/09/2007, Reviewed: 09/16/2008) - Zoledronic acid can prevent treatment-induced bone loss in premenopausal women undergoing total estrogen suppression after surgery for hormone-responsive breast cancer, according to an article published online Jan. 3, 2007, in the Journal of Clinical Oncology.
< Previous  1 2 3 4 5 6 7   Next >

A Service of the National Cancer Institute
Department of Health and Human Services National Institutes of Health USA.gov